Reprogramming carcinoma associated fibroblasts by AC1MMYR2 impedes tumor metastasis and improves chemotherapy efficacy

Cancer Letters

Volumn 374, Issue 1, 2016, Pages 96-106

  Ren, Yu ^a,b   Zhou, Xuan ^c   Liu, Xia ^a   Jia, Huan huan ^a   Zhao, Xiao hui ^a   Wang, Qi xue ^a,b   Han, Lei ^a,b   Song, Xin ^a   Zhu, Zhi yan ^a   Sun, Ting ^a   Jiao, Hong xiao ^a   Tian, Wei ping ^a   Yang, Yu qi ^a   Zhao, Xiu lan ^a   Zhang, Lun ^c   Mei, Mei ^a   Kang, Chun sheng ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Binhai Neurological Institute   (China)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

AC1MMYR2; Carcinoma associated fibroblasts; Metastasis; NF kB; VHL

Indexed keywords

AC1MMYR2; ALPHA SMOOTH MUSCLE ACTIN; ANTINEOPLASTIC AGENT; BETA CATENIN; F ACTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 21; PACLITAXEL; SEPRASE; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; VON HIPPEL LINDAU PROTEIN; AC1MMYR2 COMPOUND; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA ASSOCIATED FIBROBLAST; CONTROLLED STUDY; DEPOLARIZATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FIBROBLAST; HUMAN; HUMAN CELL; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL COMMUNICATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; MCF 7 CELL LINE; METASTASIS; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; FEMALE; FIBROBLASTS; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; PYRIMIDINES; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959353005     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.02.003     Document Type: Article

References (43)

1. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
2. Gao D., Vahdat L.T., Wong S., Chang J.C., Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res 2012, 72:4883-4889.
3. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
4. De Wever O., Van Bockstal M., Mareel M., Hendrix A., Bracke M. Carcinoma-associated fibroblasts provide operational flexibility in metastasis. Semin. Cancer Biol 2014, 25:33-46.
5. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
6. Feig C., Jones J.O., Kraman M., Wells R.J., Deonarine A., Chan D.S., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:20212-20217.
7. Ostman A., Augsten M. Cancer-associated fibroblasts and tumor growth - bystanders turning into key players. Curr. Opin. Genet. Dev 2009, 19:67-73.
8. Busch S., Acar A., Magnusson Y., Gregersson P., Ryden L., Landberg G. TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer. Oncogene 2015, 34:27-38.
9. Pena C., Cespedes M.V., Lindh M.B., Kiflemariam S., Mezheyeuski A., Edqvist P.H., et al. STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res 2013, 73:1287-1297.
10. Yamamura Y., Asai N., Enomoto A., Kato T., Mii S., Kondo Y., et al. Akt-Girdin signaling in cancer-associated fibroblasts contributes to tumor progression. Cancer Res 2015, 75:813-823.
11. Sanz-Moreno V., Gaggioli C., Yeo M., Albrengues J., Wallberg F., Viros A., et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 2011, 20:229-245.
12. Hartman Z.C., Yang X.Y., Glass O., Lei G., Osada T., Dave S.S., et al. HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res 2011, 71:4380-4391.
13. Su S., Liu Q., Chen J., Chen J., Chen F., He C., et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 2014, 25:605-620.
14. Song S.J., Poliseno L., Song M.S., Ala U., Webster K., Ng C., et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013, 154:311-324.
15. Shi M., Liu D., Duan H., Shen B., Guo N. Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev 2010, 29:785-799.
16. Kohlhapp F.J., Mitra A.K., Lengyel E., Peter M.E. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene 2015, 34:5857-5868.
17. Su Y., Li X., Ji W., Sun B., Xu C., Li Z., et al. Small molecule with big role: MicroRNAs in cancer metastatic microenvironments. Cancer Lett 2014, 344:147-156.
18. Asaga S., Kuo C., Nguyen T., Terpenning M., Giuliano A.E., Hoon D.S. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem 2011, 57:84-91.
19. Qian B., Katsaros D., Lu L., Preti M., Durando A., Arisio R., et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res. Treat 2009, 117:131-140.
20. Li Q., Zhang D., Wang Y., Sun P., Hou X., Larner J., et al. MiR-21/Smad 7 signaling determines TGF-beta1-induced CAF formation. Sci. Rep 2013, 3:2038.
21. Ren Y., Zhou X., Yang J.J., Liu X., Zhao X.H., Wang Q.X., et al. AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis. Cancer Lett 2015, 362:174-182.
22. Shi Z., Zhang J., Qian X., Han L., Zhang K., Chen L., et al. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression. Cancer Res 2013, 73:5519-5531.
23. Erez N., Truitt M., Olson P., Arron S.T., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-Dependent manner. Cancer Cell 2010, 17:135-147.
24. Cufi S., Bonavia R., Vazquez-Martin A., Oliveras-Ferraros C., Corominas-Faja B., Cuyas E., et al. Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Sci. Rep 2013, 3:2459.
25. Bao B., Ali S., Ahmad A., Azmi A.S., Li Y., Banerjee S., et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS ONE 2012, 7:e50165.
26. Wang J.Y., Gao Y.B., Zhang N., Zou D.W., Wang P., Zhu Z.Y., et al. miR-21 overexpression enhances TGF-beta1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol. Cell. Endocrinol 2014, 392:163-172.
27. De Mattos-Arruda L., Bottai G., Nuciforo P.G., Di Tommaso L., Giovannetti E., Peg V., et al. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget 2015, 6:37269-37280.
28. Martinez-Outschoorn U.E., Curry J.M., Ko Y.H., Lin Z., Tuluc M., Cognetti D., et al. Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFkappaB target stromal MCT4. Cell Cycle 2013, 12:2580-2597.
29. Madhyastha R., Madhyastha H., Pengjam Y., Nakajima Y., Omura S., Maruyama M. NFkappaB activation is essential for miR-21 induction by TGFbeta1 in high glucose conditions. Biochem. Biophys. Res. Commun 2014, 451:615-621.
30. Niu J., Shi Y., Tan G., Yang C.H., Fan M., Pfeffer L.M., et al. DNA damage induces NF-kappaB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. J. Biol. Chem 2012, 287:21783-21795.
31. Srivastava K., Hu J., Korn C., Savant S., Teichert M., Kapel S.S., et al. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell 2014, 26:880-895.
32. Cramer T., Yamanishi Y., Clausen B.E., Förster I., Pawlinski R., Mackman N., et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 2003, 112:645-657.
33. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
34. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med 2013, 19:1423-1437.
35. Costa A., Scholer-Dahirel A., Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin. Cancer Biol 2014, 25:23-32.
36. Toullec A., Gerald D., Despouy G., Bourachot B., Cardon M., Lefort S., et al. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol. Med 2010, 2:211-230.
37. Martinez-Outschoorn U.E., Balliet R.M., Rivadeneira D.B., Chiavarina B., Pavlides S., Wang C., et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010, 9:3256-3276.
38. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
39. Kisseleva T., Song L., Vorontchikhina M., Feirt N., Kitajewski J., Schindler C. NF-kappaB regulation of endothelial cell function during LPS-induced toxemia and cancer. J. Clin. Invest 2006, 116:2955-2963.
40. Mueller L., Goumas F.A., Affeldt M., Sandtner S., Gehling U.M., Brilloff S., et al. Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am. J. Pathol 2007, 171:1608-1618.
41. Mitra A.K., Zillhardt M., Hua Y., Tiwari P., Murmann A.E., Peter M.E., et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov 2012, 2:1100-1108.
42. Musumeci M., Coppola V., Addario A., Patrizii M., Maugeri-Sacca M., Memeo L., et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011, 30:4231-4242.
43. Zhang K.L., Han L., Chen L.Y., Shi Z.D., Yang M., Ren Y., et al. Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas. Cancer Lett 2014, 342:139-149.